SCHEMBL5673786

SCHEMBL5673786

CSCCC(N)C(C)=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5672851 1.00
SCHEMBL15225393 1.00
Racemethionine SCHEMBL27468619 0.82 BHMT (0.53)
SCHEMBL12681647 0.82 NOS2 (0.41)
Methionine SCHEMBL28674376 0.82 BHMT (0.53)
Racemethionine SCHEMBL23361954 0.81 BHMT (0.57)
Racemethionine SCHEMBL8983115 0.81 BHMT (0.57)
Methionine SCHEMBL4226 0.81
Racemethionine SCHEMBL126688 0.81
SCHEMBL3316021 0.81

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023205786-A1 DIDEHYDRO-3'-DEOXY-4'-ETHYNYLTHYMIDINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS ROME THERAPEUTICS, INC. (US) 2023-10-26 WO disclosed
WO-2023015533-A1 SYNTHETIC PEPTIDE, AND COSMETIC COMPOSITION OR PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF 深圳市维琪医药研发有限公司 2023-02-16 WO disclosed
US-20220387633-A1 SMART PEPTIDES AND TRANSFORMABLE NANOPARTICLES FOR CANCER IMMUNOTHERAPY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2022-12-08 US disclosed
US-20200129445-A1 LIPID NANOPARTICLE FORMULATION ARES CAPITAL CORPORATION, AS AGENT 2020-04-30 US disclosed
WO-2018102508-A1 COMPOUNDS USEFUL FOR THE TREATMENT AND/OR CARE OF THE SKIN, HAIR, NAILS AND/OR MUCOUS MEMBRANES LUBRIZOL ADVANCED MATERIALS, INC. (US) 2018-06-07 WO disclosed
US-20180148390-A1 METHOD AND COMPOSITION FOR RETAINING NUTRIENTS IN SOIL AT PLANTING SITES WATERSCIENCE, INC. (US) 2018-05-31 US disclosed
WO-2018081303-A1 METHOD AND COMPOSITION FOR RETAINING NUTRIENTS IN SOIL AT PLANTING SITES WATERSCIENCE, INC. (US) 2018-05-03 WO disclosed
US-20170137380-A1 IONIC LIQUID FILMS WITH MULTIPLE FUNCTIONALITIES FOR SURFACE MODIFICATION OF BIOMEDICAL ALLOYS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2017-05-18 US disclosed
EP-2773366-B1 PEPTIDES WHICH INHIBIT ACTIVATED RECEPTORS AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS LIPOTEC SA (ES) 2017-03-01 EP disclosed
US-9403764-B2 Method of production of a methionine salt EVONIK DEGUSSA GMBH (DE) 2016-08-02 US disclosed
US-20090170845-A1 USE OF IMIDAZO[2,1-b]-1,3,4-THIADIAZOLE-2-SULFONAMIDE COMPOUNDS TO TREAT NEUROPATHIC PAIN AEGERA THERAPEUTICS INC. (CA) 2009-07-02 US disclosed
US-7521466-B2 Dipeptide phenyl ethers BEXEL PHARMACEUTICALS, INC. (US) 2009-04-21 US disclosed
US-7521466-B2 Dipeptide phenyl ethers BEXEL PHARMACEUTICALS, INC. (US) 2009-04-21 US disclosed
US-20070112043-A1 Acylated and non-acylated imidazo[2,1-b]-1,3,4,-thiadiazole-2-sulfonamides, and uses thereof AEGERA THERAPEUTICS, INC. (CA) 2007-05-17 US disclosed
US-20070037863-A1 such as 5-[4-(4-(2-(2-amino-3-imidazol-4-yl propanamido)-2-methoxy carobonylethyl)phenoxy)benzylidene]thiazolidin-2,4-dione, used for lowering blood glucose, serum insulin, free fatty acids, cholesterol and triglyceride levels; prophylaxis of diabetes, obesity, inflammation and autoimmune diseases NAG BISHWAJIT 2007-02-15 US disclosed
US-20070037863-A1 such as 5-[4-(4-(2-(2-amino-3-imidazol-4-yl propanamido)-2-methoxy carobonylethyl)phenoxy)benzylidene]thiazolidin-2,4-dione, used for lowering blood glucose, serum insulin, free fatty acids, cholesterol and triglyceride levels; prophylaxis of diabetes, obesity, inflammation and autoimmune diseases NAG BISHWAJIT 2007-02-15 US disclosed
WO-2007001926-A2 LOW-SWELLING HYDROGEL SEALANTS FOR WOUND REPAIR HYPERBRANCH MEDICAL TECHNOLOGY, INC. (US) 2007-01-04 WO disclosed
EP-1660436-A4 CATHEPSIN INHIBITORS MERCK FROSST CANADA LTD (CA) 2006-11-22 EP disclosed
EP-1660436-A1 CATHEPSIN INHIBITORS Merck Frosst Canada Ltd. (CA) 2006-05-31 EP disclosed
WO-2005021487-A1 CATHEPSIN INHIBITORS MERCK FROSST CANADA LTD. (CA) 2005-03-10 WO disclosed